MAZE THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MAZE THERAPEUTICS, INC. (MAZE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $9.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $9.19M, a 183.81% increase year-over-year.
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.11M, a 120.37% increase year-over-year.
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.86M, a 64.92% increase year-over-year.
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.24M, a 51.12% increase year-over-year.
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $16.40M, a 70.02% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $9.65M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.19M 10-Q · filed 2026-08-11 | $16.30M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $7.11M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $16.40M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $3.86M 10-Q · filed 2025-11-06 | $7.10M derived: sum of 2 quarters · filed 2026-08-11 | $10.33M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.24M 10-Q · filed 2026-08-11 | $6.46M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $3.23M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $9.65M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $2.34M 10-Q · filed 2025-11-06 | $4.49M derived: sum of 2 quarters · filed 2025-11-06 | $6.79M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.14M 10-Q · filed 2025-11-06 | $4.45M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $2.31M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |